The FDA has spent years trying to push sodium lower in the American food supply through voluntary reformulation targets aimed at packaged foods and restaurant items. New findings presented in the Washington, D.C., area on July 25 suggest that effort has not translated into less sodium in the kinds of new packaged foods showing up on store shelves. The research points to a gap between federal guidance and what manufacturers are actually introducing to U.S. shoppers.
A 10-year review found no overall sodium decline in new packaged foods
Researchers from the Johns Hopkins Bloomberg School of Public Health reported July 25 at NUTRITION 2026 in National Harbor, Maryland, that sodium levels in newly introduced packaged foods did not fall overall after the FDA issued Phase I voluntary sodium reduction targets in 2021, according to the conference abstract and a Johns Hopkins-issued release. The analysis covered products launched in the United States from 2015 through 2025, giving the team six years of pre-guidance data and four years of post-guidance data. It focused on nine major sodium-contributing packaged food categories, including breads, pizzas, sandwiches and wraps, meat products, corn-based snacks, potato snacks, popcorn, dry soups and wet soups.
Across all nine categories combined, the sodium content of new products introduced after 2021 did not differ from products launched before the guidance, according to the researchers. The study also found higher sodium levels in four categories after the FDA action: dry soups, popcorn, bread and bread products, and corn-based snacks. Lead author Kenny Kusnadi said the findings suggest the industry is not incorporating the FDA’s sodium targets into new product development.
The researchers said their analysis relied on Nutrition Facts label data from the Mintel Global New Product Database, which tracks newly introduced products and items with formulation or packaging changes sold through supermarkets and other major retail channels. They also cautioned that the work does not measure all products currently sold in stores and has not yet undergone the full peer-review process required for journal publication. That means the findings are preliminary, even as they offer an early look at whether the guidance changed product innovation.
What the findings do and do not say about store shelves in the D.C. region
Because the study was presented at a national nutrition meeting in National Harbor, just outside Washington, the immediate local tie is geographic rather than product-specific. The researchers analyzed products introduced to the U.S. market broadly, not items sold only in Maryland, the District of Columbia or Northern Virginia, and they did not publish a regional breakout for shelves in the Capital region. That means there is no confirmed list showing which specific grocery products in local stores were examined.
What is confirmed is that the product database used in the study covers packaged foods sold in supermarkets and major retail channels in the United States. In practical terms, that means the findings speak to the kinds of products consumers are likely to encounter in mainstream grocery aisles, but not to a store-by-store inventory in Prince George’s County, the District or nearby suburbs. The researchers also did not identify brands in the public summary.
The FDA’s broader sodium initiative remains national in scope. The agency said in August 2024 that it had moved into Phase II by issuing draft voluntary sodium targets for certain foods, building on the Phase I goals first finalized in October 2021. FDA materials also state that the agency plans to issue a formal evaluation of the Phase I targets in 2026, which could provide a fuller picture of whether sodium levels have shifted across the food supply beyond newly launched products.
Why regulators are still leaning on voluntary targets, and what shoppers should expect
The FDA’s Phase I guidance was designed as a short-term, voluntary program for 163 categories of processed, packaged and prepared foods. When the agency issued that guidance in 2021, it said the goal was to reduce average U.S. sodium intake from about 3,400 milligrams per day to roughly 3,000 milligrams over 2.5 years. The agency has since described the effort as a stepwise strategy, with Phase II draft targets released on August 15, 2024.
Johns Hopkins researchers say the new findings raise questions about whether a voluntary framework is strong enough to influence industry behavior. Senior author Matti Marklund said the available evidence suggests non-binding targets are a less effective way to drive meaningful sodium reductions and that stronger accountability mechanisms may be needed. The researchers linked the issue to well-established health concerns, noting that excess sodium intake remains a leading contributor to hypertension and raises the risk of stroke, heart attack and heart failure.
For shoppers, the immediate takeaway is limited: this study does not show a broad reduction in sodium among new packaged foods entering the market, so lower-sodium reformulation may not yet be visible at the shelf level. It also does not mean every product category moved in the same direction or that all existing products remained unchanged. The FDA has said a formal Phase I evaluation is due in 2026, and that review is likely to shape how much confidence consumers and manufacturers place in the next phase of the agency’s sodium strategy.